EPSTEIN‐BARR VIRUS‐DRIVEN DISEASES: A MULTINATIONAL, MULTICOHORT, OPEN‐LABEL PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF TABELECLEUCEL USING AN ADAPTIVE STUDY DESIGN. (17th June 2021) - Choquet, S.; Pérez‐Simón, J. A.; Worel, N.; Chaganti, S.; Dinavahi, R.; Guzman‐Becerra, N.; Navarro, W.; Sun, Y.; Gamelin, L.